RESUMO
Endocannabinoids play a role in adaptation to stress and regulate the release of glucocorticoids in stressed and unstressed conditions. We recently found that basal corticosterone pulsatility may significantly impact the vulnerability for developing post-traumatic-stress-disorder (PTSD), suggesting that the endocannabinoid system may contribute to its development. To examine this, we exposed rats to predator scent stress (PSS). Behavioral reactions were recorded seven days post-PSS. Cerebrospinal fluid (CSF) was collected from anesthetized rats shortly after PSS exposure to determine the levels of 2-arachidonoyl glycerol (2-AG) and anandamide (AEA). To correlate between endocannabinoids and corticosterone levels, rats were placed in metabolic cages for urine collection. To assess the levels of endocannabinoids in specific brain regions, rats' brains were harvested one day after behavioral analysis for staining and fluorescence quantification. Moreover, 2-AG was elevated in the CSF of PTSD-phenotype rats as compared with other groups and was inversely correlated with corticosterone urinary secretion. Eight days post-PSS exposure, hippocampal and hypothalamic 2-AG levels and hippocampal AEA levels were significantly more reduced in the PTSD-phenotype group compared to other groups. We posit that maladaptation to stress, which is propagated by an abnormal activation of endocannabinoids, mediates the subsequent stress-induced behavioral disruption, which, later, reduces neuronal the expression of endocannabinoids, contributing to PTSD symptomology.
Assuntos
Endocanabinoides/metabolismo , Sistema Hipotálamo-Hipofisário/fisiologia , Sistema Hipófise-Suprarrenal/patologia , Transtornos de Estresse Pós-Traumáticos/patologia , Estresse Psicológico/complicações , Estresse Psicológico/metabolismo , Animais , Comportamento Animal , Corticosterona/urina , Endocanabinoides/líquido cefalorraquidiano , Masculino , Fenótipo , Ratos Sprague-Dawley , Transtornos de Estresse Pós-Traumáticos/urina , Estresse Psicológico/urinaRESUMO
This work describes the development and validation of an ultra-high performance liquid chromatography tandem mass spectrometry method that uses disposable pipette extraction (DPX-UHPLC-MS/MS) to determine the endocannabinoid anandamide (AEA) in cerebrospinal fluid samples (CSF). The DPX parameters sorption equilibrium time, sample volume, number of draw-eject cycles, washing solvent volume, and elution solvent volume were optimized by design of experiments (DOE) techniques. The simple DPX protocol proposed herein required a reduced amount of CSF sample and organic solvent. The DPX-UHPLC-MS/MS method presented linear range from 0.10â¯ngâ¯mL-1 (LLOQ) to 3.0â¯ngâ¯mL-1, inter- and intra-assay accuracy with EPR values varying from -8.2% to 9.6%, inter- and intra-assay precision with CV values ranging from 1.3% to 14.8% (except for the LLOQ), and no significant matrix effect. The innovative DPX-UHPLC-MS/MS method was successfully applied to determine AEA in CSF samples from Parkinson's disease (PD) patients and should therefore be used in clinical studies.
Assuntos
Ácidos Araquidônicos/líquido cefalorraquidiano , Cromatografia Líquida de Alta Pressão/métodos , Endocanabinoides/líquido cefalorraquidiano , Alcamidas Poli-Insaturadas/líquido cefalorraquidiano , Espectrometria de Massas em Tandem/métodos , Ácidos Araquidônicos/isolamento & purificação , Endocanabinoides/isolamento & purificação , Humanos , Modelos Lineares , Alcamidas Poli-Insaturadas/isolamento & purificação , Reprodutibilidade dos Testes , Sensibilidade e EspecificidadeRESUMO
Importance: The endocannabinoid system (ECS) is a lipid-based endogenous signaling system. Its relevance to psychosis is through the association between cannabis use and the onset and course of illness and through the antipsychotic properties of cannabidiol, a potential ECS enhancer. Objective: To conduct a systematic review and meta-analysis of the blood and cerebrospinal fluid (CSF) measures of the ECS in psychotic disorders. Data Sources: Web of Science and PubMed were searched from inception through June 13, 2018. The articles identified were reviewed, as were citations to previous publications and the reference lists of retrieved articles. Study Selection: Original articles were included that reported blood or CSF measures of ECS activity in patients with psychotic illnesses and in healthy controls. Data Extraction and Synthesis: PRISMA guidelines, independent extraction by multiple observers, and random-effects meta-analysis were used. Heterogeneity was assessed with the I2 index. Sensitivity analyses tested the robustness of the results. Main Outcomes and Measures: The clinical relevance of ECS modifications in psychotic disorders was investigated by (1) a quantitative synthesis of the differences in blood and CSF markers of the ECS between patients and healthy controls, and (2) a qualitative synthesis of the association of these markers with symptom severity, stage of illness, and response to treatment. Results: A total of 18 studies were included. Three individual meta-analyses were performed to identify the differences in ECS markers between people with schizophrenia and healthy controls. Five studies, including 226 patients and 385 controls, reported significantly higher concentrations of anandamide in the CSF of patients than controls (standardized mean difference [SMD], 0.97; 95% CI, 0.67-1.26; P < .001; I2 = 54.8%). In 9 studies, with 344 patients and 411 controls, significantly higher anandamide levels in blood were found in patients, compared with controls (SMD, 0.55; 95% CI, 0.05-1.04; P = .03; I2 = 89.6%). In 3 studies, involving 88 patients and 179 controls, a significantly higher expression of type 1 cannabinoid receptors on peripheral immune cells was reported in patients compared with controls (SMD, 0.57; 95% CI, 0.31-0.84; P < .001; I2 = 0%). Higher ECS tone was found at an early stage of illness in individuals who were antipsychotic naïve or free, and it had an inverse association with symptom severity and was normalized after successful treatment. Moderate to high level of heterogeneity in methods was found between studies. Conclusions and Relevance: Testing clinically relevant markers of the ECS in the blood and CSF of people with psychotic illness appears possible, and these markers provide useful biomarkers for the psychotic disorder; however, not all studies accounted for important variables, such as cannabis use. Trial Registration: PROSPERO identifier: CRD42018099863.
Assuntos
Biomarcadores/metabolismo , Endocanabinoides/metabolismo , Transtornos Psicóticos/metabolismo , Biomarcadores/sangue , Biomarcadores/líquido cefalorraquidiano , Endocanabinoides/sangue , Endocanabinoides/líquido cefalorraquidiano , Humanos , Transtornos Psicóticos/sangue , Transtornos Psicóticos/líquido cefalorraquidianoRESUMO
Neuroinfections are a significant medical problem and can have serious health consequences for patients. Their outcome, if not fatal, can be associated with permanent residual deficits. Cerebrospinal fluid (CSF) examination is commonly used for meningitis confirmation. Fatty acids (FA) are precursors of lipid mediators with pharmacological activity. They actively modulate inflammation as well as contribute to its resolution. Therefore the aim of this study was to determine the FA and selected endocannabinoids (ECB) content in the CSF obtained from patients with bacterial (BM) and viral meningitis (VM) using chromatographic techniques. A significantly lower level of saturated FA was found in patients with BM and VM as compared to controls. There was a significantly higher concentration of long-chain monounsaturated FA and polyunsaturated n-6 FA in the CSF obtained from patients with neuroinfection. Moreover, a significant reduction of n-3 FA in CSF obtained from patients with BM and VM was demonstrated. The highest amount of ECB was detected in the CSF of patients with VM: eicosapentaenoyl ethanolamide (1.65 pg/mL), docosahexaenoyl ethanolamide (655.5 pg/mL) and nervonoyl ethanolamide (3.09 ng/mL). Results indicate the participation of long-chain monounsaturated and polyunsaturated FA and their derivatives in the inflammatory process and likely in the process of resolution of inflammation during neuroinfection. It seems that the determination of the FA and ECB profile in CSF may be a valuable biomarker of health and may allow the development of new pharmacological strategies, therapeutic goals and fatty acids supplementation necessary in the fight against inflammation of the central nervous system.
Assuntos
Endocanabinoides/líquido cefalorraquidiano , Ácidos Graxos/líquido cefalorraquidiano , Meningites Bacterianas/líquido cefalorraquidiano , Meningite Viral/líquido cefalorraquidiano , Biomarcadores/líquido cefalorraquidiano , Feminino , Humanos , MasculinoRESUMO
BACKGROUND: No candidate biomarkers based on cerebrospinal fluid (CSF) have been identified as prognostic factors in patients with major depression treated with electroconvulsive therapy (ECT), yet. METHOD: Following different underlying hypotheses, we analysed baseline CSF levels of markers of neurodegeneration (tau proteins, ß-amyloids and neurogranin), elements of the innate immune system (interleukin [IL]-6, neopterin, soluble CD14, soluble CD163, migration inhibitory factor and monocyte chemotactic protein 1), endocannabinoids, sphingolipids and Klotho before ECT in patients with depression (n = 12) to identify possible correlations with the clinical antidepressant response to ECT. RESULTS: Correlation with the reduction of the depressive symptoms could be observed especially for markers of neurodegeneration and elements of the innate immune system. Differences for CSF levels of several markers were found between the groups of responders and non-responders at the trend level. LIMITATIONS: The sample size is small and the -distribution of responders and non-responders is uneven. CONCLUSIONS: It is this first study on CSF biomarkers for antidepressant efficacy of ECT warrants further research regarding the mechanism of ECT and personalized antidepressant therapy.
Assuntos
Transtorno Depressivo Maior/líquido cefalorraquidiano , Transtorno Depressivo Maior/terapia , Eletroconvulsoterapia , Endocanabinoides/líquido cefalorraquidiano , Glucuronidase/líquido cefalorraquidiano , Imunidade Inata , Degeneração Neural/líquido cefalorraquidiano , Esfingolipídeos/líquido cefalorraquidiano , Adulto , Idoso , Idoso de 80 Anos ou mais , Biomarcadores/líquido cefalorraquidiano , Feminino , Humanos , Proteínas Klotho , Masculino , Pessoa de Meia-Idade , Resultado do Tratamento , Adulto JovemRESUMO
Inhibition of fatty acid amide hydrolase (FAAH) potentiates endocannabinoid activity and is hypothesized to have therapeutic potential for mood and anxiety disorders and pain. The clinical profile of JNJ-42165279, an oral selective FAAH inhibitor, was assessed by investigating the pharmacokinetics, pharmacodynamics, safety, and binding to FAAH in the brain of healthy human volunteers. Concentrations of JNJ-42165279 (plasma, cerebrospinal fluid (CSF), urine) and fatty acid amides (FAA; plasma, CSF), and FAAH activity in leukocytes was determined in a phase I multiple ascending dose study. A positron emission tomography study with the FAAH tracer [11 C]MK3168 was conducted to determine brain FAAH occupancy after single and multiple doses of JNJ-42165279. JNJ-42165279 administration resulted in an increase in plasma and CSF FAA. Significant blocking of brain FAAH binding of [11 C]MK3168 was observed after pretreatment with JNJ-42165279. JNJ-42165279 produces potent central and peripheral FAAH inhibition. Saturation of brain FAAH occupancy occurred with doses ≥10 mg of JNJ-42165279. No safety concerns were identified.
Assuntos
Amidoidrolases/antagonistas & inibidores , Encéfalo/metabolismo , Endocanabinoides/metabolismo , Inibidores Enzimáticos/farmacologia , Piperazinas/farmacologia , Administração Oral , Adulto , Idoso , Idoso de 80 Anos ou mais , Amidoidrolases/metabolismo , Encéfalo/diagnóstico por imagem , Encéfalo/efeitos dos fármacos , Relação Dose-Resposta a Droga , Endocanabinoides/sangue , Endocanabinoides/líquido cefalorraquidiano , Feminino , Voluntários Saudáveis , Humanos , Leucócitos/efeitos dos fármacos , Leucócitos/metabolismo , Masculino , Pessoa de Meia-Idade , Imagem Molecular/métodos , Tomografia por Emissão de Pósitrons/métodos , Traçadores Radioativos , Adulto JovemRESUMO
Endocannabinoids (ECs) are involved in immunomodulation, neuroprotection and control of inflammation in the central nervous system (CNS). Activation of cannabinoid type 2 receptors (CB2) is known to diminish the release of pro-inflammatory factors and enhance the secretion of anti-inflammatory cytokines. Furthermore, the endocannabinoid 2-arachidonoyl glycerol (2-AG) has been proved to induce the migration of eosinophils in a CB2 receptor-dependent manner in peripheral blood and activate neutrophils independent of CB activation in humans. The aim of the current study was to investigate the influence of the endocannabinoid system in two different CNS inflammatory diseases of the dog, i.e. Steroid-Responsive Meningitis-Arteritis (SRMA) and Intraspinal Spirocercosis (IS). The two main endocannabinoids, anandamide (AEA) and 2-AG, were quantified by mass spectrometry in CSF and serum samples of dogs affected with Steroid- Responsive Meningitis-Arteritis in the acute phase (SRMA A), SRMA under treatment with prednisolone (SRMA Tr), intraspinal Spirocercosis and healthy dogs. Moreover, expression of the CB2 receptor was evaluated in inflammatory lesions of SRMA and IS and compared to healthy controls using immunohistochemistry (IHC). Dogs with SRMA A showed significantly higher concentrations of total AG and AEA in serum in comparison to healthy controls and in CSF compared to SRMA Tr (p<0.05). Furthermore, dogs with IS displayed the highest ECs concentrations in CSF, being significantly higher than in CSF samples of dogs with SRMA A (p<0.05). CSF samples that demonstrated an eosinophilic pleocytosis had the highest levels of ECs, exceeding those with neutrophilic pleocytosis, suggesting that ECs have a major effect on migration of eosinophils in the CSF. Furthermore, CB2 receptor expression was found in glial cells in the spinal cord of healthy dogs, whereas in dogs with SRMA and IS, CB2 was strongly expressed not only in glial cells but also on the cellular surface of infiltrating leukocytes (i.e. neutrophils, eosinophils, lymphocytes, plasma cells, and macrophages) at lesion sites. The present study revealed an upregulated endocannabinoid system in dogs with inflammatory CNS diseases, highlighting the endocannabinoid system as a potential target for treatment of inflammatory CNS diseases.
Assuntos
Arterite/veterinária , Doenças do Cão/fisiopatologia , Endocanabinoides/fisiologia , Meningite/veterinária , Doenças da Coluna Vertebral/veterinária , Infecções por Spirurida/veterinária , Animais , Arterite/sangue , Arterite/líquido cefalorraquidiano , Arterite/fisiopatologia , Cromatografia Líquida , Doenças do Cão/sangue , Doenças do Cão/líquido cefalorraquidiano , Cães , Endocanabinoides/sangue , Endocanabinoides/líquido cefalorraquidiano , Espectrometria de Massas , Meningite/sangue , Meningite/líquido cefalorraquidiano , Meningite/fisiopatologia , Doenças da Coluna Vertebral/sangue , Doenças da Coluna Vertebral/líquido cefalorraquidiano , Doenças da Coluna Vertebral/fisiopatologia , Infecções por Spirurida/sangue , Infecções por Spirurida/líquido cefalorraquidiano , Infecções por Spirurida/fisiopatologia , Espectrometria de Massas em TandemRESUMO
Despite the lack of clinical data about the role of the endocannabinoid system (ECS) in affective disorders, preclinical work suggests that the ECS is relevant in both with regard to the etiology of depression as well as the mediation of antidepressant effects. We measured the intraindividual levels of the endocannabinoids N-arachidonoylethanolamine (AEA) and 2-arachidonoylglycerol (2-AG) in the cerebrospinal fluid of 12 patients suffering from a major depressive episode before and after the antidepressant treatment by electroconvulsive therapy (ECT). AEA was significantly elevated after ECT as compared to baseline. The AEA increase positively correlated with the number of individually performed ECT sessions. Although the sample size was small and confounders were not rigorously controlled for, our finding corroborates preclinical work and should encourage further exploration of the involvement of the ECS in depressive disorder.
Assuntos
Transtorno Depressivo Maior/líquido cefalorraquidiano , Transtorno Depressivo Maior/terapia , Eletroconvulsoterapia/métodos , Endocanabinoides/líquido cefalorraquidiano , Adulto , Idoso , Idoso de 80 Anos ou mais , Ácidos Araquidônicos/líquido cefalorraquidiano , Feminino , Glicerídeos/líquido cefalorraquidiano , Humanos , Masculino , Pessoa de Meia-Idade , Alcamidas Poli-Insaturadas , Estudos Prospectivos , Adulto JovemRESUMO
OBJECTIVES: Binocular depth inversion illusion (BDII) represents an illusion of visual perception that involves higher-order visual and cognitive processes. Its impairment has been linked to psychotic conditions and identified as a marker for at-risk mental states. The endogenous cannabinoid system (ECS) is involved in various neurophysiological processes. One of its key components, anandamide, is involved in the pathophysiology of schizophrenia. Little is known about its impact on BDII alterations. Therefore, we explored associations between BDII and anandamide levels. METHODS: BDII was conducted and blood and CSF were taken in 28 first-episode antipsychotic-naïve schizophrenia (SZ) patients and 81 healthy controls (HC). Serum and CSF anandamide levels were determined by high-performance liquid chromatography/mass spectrometry. RESULTS: BDII scores were significantly elevated in SZ versus HC, indicating a disruption of illusionary revision of percepts in SZ. Anandamide levels were significantly higher in CSF of SZ compared to HC, while serum anandamide was not. However, we found specific association differences of anandamide levels and BDII scores between schizophrenia patients and controls in serum. CONCLUSIONS: These findings support the hypothesis of an involvement of anandamide in cognitive processes impaired in schizophrenia and are consistent with a protective effect of elevated anandamide levels herein.
Assuntos
Ácidos Araquidônicos/metabolismo , Percepção de Profundidade/fisiologia , Endocanabinoides/metabolismo , Ilusões/fisiologia , Alcamidas Poli-Insaturadas/metabolismo , Esquizofrenia/metabolismo , Esquizofrenia/fisiopatologia , Percepção Visual/fisiologia , Adulto , Ácidos Araquidônicos/sangue , Ácidos Araquidônicos/líquido cefalorraquidiano , Endocanabinoides/sangue , Endocanabinoides/líquido cefalorraquidiano , Feminino , Humanos , Masculino , Alcamidas Poli-Insaturadas/sangue , Alcamidas Poli-Insaturadas/líquido cefalorraquidiano , Adulto JovemRESUMO
Endocannabinoids, a class of lipid messengers, have emerged as crucial regulators of synaptic communication in the CNS. Dysregulation of these compounds has been implicated in many brain disorders. Although some studies have identified and quantified a limited number of target compounds, a method that provides comprehensive quantitative information on endocannabinoids and related N-acylethanolamines (NAEs) in cerebrospinal fluid (CSF) is currently lacking, as measurements are challenging due to low concentrations under normal physiological conditions. Here we developed and validated a high-throughput nano LC-ESI-MS/MS platform for the simultaneous quantification of endocannabinoids (anandamide and 2-arachidonoylglycerol), ten related NAEs, and eight additional putatively annotated NAEs in human CSF. Requiring only 200 µl of CSF, our method has limits of detection from 0.28 to 61.2 pM with precisions of relative SD <15% for most compounds. We applied our method to CSF from 45 healthy humans and demonstrated potential age and gender effects on concentrations of endocannabinoids and NAEs. Notably, our results show that docosahexaenoylethanolamide concentrations increase with age in males. Our method may offer new opportunities to gain insight into regulatory functions of endocannabinoids in the context of (ab)normal brain function.
Assuntos
Ácidos Araquidônicos/líquido cefalorraquidiano , Endocanabinoides/líquido cefalorraquidiano , Etanolaminas/líquido cefalorraquidiano , Glicerídeos/líquido cefalorraquidiano , Alcamidas Poli-Insaturadas/líquido cefalorraquidiano , Adulto , Fatores Etários , Cromatografia Líquida/métodos , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Caracteres Sexuais , Espectrometria de Massas em Tandem/métodosRESUMO
BACKGROUND: There is compelling evidence in humans that peripheral endocannabinoid signaling is disrupted in obesity. However, little is known about the corresponding central signaling. Here, we have investigated the relationship between gender, leptin, body mass index (BMI) and levels of the endocannabinoids anandamide (AEA) and 2-arachidonoylglycerol (2-AG) in the serum and cerebrospinal fluid (CSF) of primarily overweight to obese patients with osteoarthritis. METHODOLOGY/PRINCIPAL FINDINGS: Patients (20 females, 15 males, age range 44-78 years, BMI range 24-42) undergoing total knee arthroplasty for end-stage osteoarthritis were recruited for the study. Endocannabinoids were quantified by liquid chromatography - mass spectrometry. AEA and 2-AG levels in the serum and CSF did not correlate with either age or BMI. However, 2-AG levels in the CSF, but not serum, correlated negatively with CSF leptin levels (Spearman's ρ -0.48, P=0.0076, n=30). No such correlations were observed for AEA and leptin. CONCLUSIONS/SIGNIFICANCE: In the patient sample investigated, there is a negative association between 2-AG and leptin levels in the CSF. This is consistent with pre-clinical studies in animals, demonstrating that leptin controls the levels of hypothalamic endocannabinoids that regulate feeding behavior.
Assuntos
Endocanabinoides/sangue , Endocanabinoides/líquido cefalorraquidiano , Leptina/sangue , Osteoartrite/sangue , Osteoartrite/líquido cefalorraquidiano , Adulto , Idoso , Ácidos Araquidônicos/sangue , Ácidos Araquidônicos/líquido cefalorraquidiano , Artroplastia do Joelho , Índice de Massa Corporal , Cromatografia Líquida , Feminino , Glicerídeos/sangue , Glicerídeos/líquido cefalorraquidiano , Humanos , Masculino , Espectrometria de Massas , Pessoa de Meia-Idade , Obesidade/sangue , Obesidade/líquido cefalorraquidiano , Osteoartrite/cirurgia , Alcamidas Poli-Insaturadas/sangue , Alcamidas Poli-Insaturadas/líquido cefalorraquidianoRESUMO
Osteoarthritis (OA) of the knee is a progressive disease that is associated with inflammation of the joints and lower extremity pain. Total knee arthroplasty (TKA) is a surgical procedure that aims to reduce pain and restore motor function in patients suffering from OA. The immediate postoperative period can be intensely painful leading to extended recovery times including persistent pain. The endocannabinoid system regulates nociception, and the activation of cannabinoid receptors produces antinociceptive effects in preclinical models of OA. To date, the influence of the endocannabinoid tone on pain and disability in OA patients and on acute postoperative pain in humans has not been explored. In this study, we provide the first comprehensive profile of endocannabinoids in serum, cerebrospinal fluid, and synovial fluid of patients with painful end-stage OA undergoing TKA and examine correlations between endocannabinoid levels, interleukin 6, functional disability, acute postoperative pain, and postoperative opioid use. Our results reveal that central (cerebrospinal fluid) and peripheral (synovial fluid) levels of the endocannabinoid 2-arachidonoyl glycerol were significantly elevated in patients who developed higher postoperative pain after TKA. In addition, synovial fluid 2-arachidonoyl glycerol levels were positively correlated with postoperative opioid use. Similarly, synovial fluid levels of the anti-inflammatory lipid palmitoylethanolamide correlated with functional disability in OA. Taken together, our results are the first to reveal associations between central and peripheral endocannabinoid levels and postoperative pain. This suggests that endocannabinoid metabolism may serve as a target for the development of novel analgesics both for systemic or local delivery into the joint.
Assuntos
Dor Aguda/metabolismo , Artroplastia do Joelho/efeitos adversos , Endocanabinoides/metabolismo , Dor Pós-Operatória/metabolismo , Líquido Sinovial/metabolismo , Dor Aguda/líquido cefalorraquidiano , Dor Aguda/diagnóstico , Idoso , Artroplastia do Joelho/tendências , Biomarcadores/líquido cefalorraquidiano , Biomarcadores/metabolismo , Endocanabinoides/líquido cefalorraquidiano , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Dor Pós-Operatória/líquido cefalorraquidiano , Dor Pós-Operatória/diagnóstico , Estudos ProspectivosRESUMO
BACKGROUND: Epilepsy is one of the most common chronic neurological disorders in dogs characterized by recurrent seizures. The endocannabinoid (EC) system plays a central role in suppressing pathologic neuronal excitability and in controlling the spread of activity in an epileptic network. Endocannabinoids are released on demand and their dysregulation has been described in several pathological conditions. Recurrent seizures may lead to an adverse reorganization of the EC system and impairment of its protective effect. In the current study, we tested the hypothesis that cerebrospinal fluid (CSF) concentrations of the endocannabinoids anandamide (AEA) and 2-arachidonoyl glycerol (2AG) are altered in epileptic dogs. Concentrations of AEA and total AG (sum of 2AG and 1AG) were measured in 40 dogs with idiopathic epilepsy and in 16 unaffected, healthy control dogs using liquid chromatography combined with tandem mass spectrometry. RESULTS: AEA and total AG were measured at 4.94 (3.18 - 9.17) pM and 1.43 (0.90 - 1.92) nM in epileptic dogs and at 3.19 (2.04 - 4.28) pM and 1.76 (1.08 - 2.69) nM in the control group, respectively (median, 25 - 75% percentiles in brackets). The AEA difference between epileptic and healthy dogs was statistically significant (p < 0.05). Values correlated with seizure severity and duration of seizure activity. Dogs with cluster seizures and/or status epilepticus and with seizure activity for more than six months displayed the highest EC concentrations. CONCLUSION: In conclusion, we present the first endocannabinoid measurements in canine CSF and confirm the hypothesis that the EC system is altered in canine idiopathic epilepsy.
Assuntos
Doenças do Cão/líquido cefalorraquidiano , Endocanabinoides/líquido cefalorraquidiano , Convulsões/veterinária , Animais , Ácidos Araquidônicos/líquido cefalorraquidiano , Estudos de Casos e Controles , Cães , Feminino , Cromatografia Gasosa-Espectrometria de Massas/veterinária , Glicerídeos/líquido cefalorraquidiano , Masculino , Alcamidas Poli-Insaturadas/líquido cefalorraquidiano , Recidiva , Convulsões/líquido cefalorraquidianoRESUMO
A significant number of patients experience chronic pain and the intractable side effects of currently prescribed pain medications. Recent evidence indicates important pain-modulatory roles for two classes of G-protein-coupled receptors that are activated by endogenous lipid ligands, the endocannabinoid (eCB) and sphingosine-1-phosphate (S1P) receptors, which are widely expressed in both the immune and nervous systems. In the central nervous system (CNS), CB1 cannabinoid and S1P1 receptors are most abundantly expressed and exhibit overlapping anatomical distributions and similar signaling mechanisms. The eCB system has emerged as a potential target for treatment of chronic pain, but comparatively little is known about the roles of S1P in pain regulation. Both eCB and S1P systems modulate pain perception via the central and peripheral nervous systems. In most paradigms studied, the eCB system mainly inhibits pain perception. In contrast, S1P acting peripherally at S1P1 and S1P3 receptors can enhance sensitivity to various pain stimuli or elicit spontaneous pain. However, S1P acting at S1P1 receptors and possibly other targets in the CNS can attenuate sensitivity to various pain stimuli. Interestingly, other endogenous sphingolipid derivatives might play a role in central pain sensitization. Moreover, these sphingolipids can also act as CB1 cannabinoid receptor antagonists, but the physiological relevance of this interaction is unknown. Overall, both eCB and sphingolipid systems offer promising targets for the treatment of chronic pain. This review compares and contrasts the eCB and S1P systems with a focus on their roles in pain modulation, and considers possible points of interaction between these systems.
Assuntos
Antagonistas de Receptores de Canabinoides/líquido cefalorraquidiano , Canabinoides/antagonistas & inibidores , Canabinoides/líquido cefalorraquidiano , Sistema Nervoso Central/fisiologia , Endocanabinoides/líquido cefalorraquidiano , Lisofosfolipídeos/líquido cefalorraquidiano , Dor/líquido cefalorraquidiano , Esfingosina/líquido cefalorraquidiano , Animais , Antagonistas de Receptores de Canabinoides/farmacologia , Antagonistas de Receptores de Canabinoides/uso terapêutico , Sistema Nervoso Central/efeitos dos fármacos , Endocanabinoides/farmacologia , Endocanabinoides/uso terapêutico , Humanos , Lisofosfolipídeos/farmacologia , Lisofosfolipídeos/uso terapêutico , Dor/tratamento farmacológico , Dor/fisiopatologia , Esfingolipídeos/líquido cefalorraquidiano , Esfingolipídeos/farmacologia , Esfingolipídeos/uso terapêutico , Esfingosina/farmacologia , Esfingosina/uso terapêuticoRESUMO
Anandamide is a ligand of the endocannabinoid system. Animals show a depletion following repeated Δ(9)-tetrahydrocannabinol (THC) administration but the effect of cannabis use on central nervous system levels of endocannabinoids has not been previously examined in humans. Cerebrospinal fluid (CSF) levels of the endocannabinoids anandamide, 2-arachidonoylglycerol (2-AG) and related lipids were tested in 33 volunteers (20 cannabis users). Lower levels of CSF anandamide and higher levels of 2-AG in serum were observed in frequent compared with infrequent cannabis users. Levels of CSF anandamide were negatively correlated with persisting psychotic symptoms when drug-free. Higher levels of anandamide are associated with a lower risk of psychotic symptoms following cannabis use.
Assuntos
Ácidos Araquidônicos/líquido cefalorraquidiano , Endocanabinoides/líquido cefalorraquidiano , Abuso de Maconha/líquido cefalorraquidiano , Alcamidas Poli-Insaturadas/líquido cefalorraquidiano , Transtornos Psicóticos/líquido cefalorraquidiano , Análise de Variância , Feminino , Glicerídeos/líquido cefalorraquidiano , Humanos , Masculino , Abuso de Maconha/psicologia , Transtornos Psicóticos/etiologia , Transdução de Sinais/efeitos dos fármacos , Adulto JovemRESUMO
There is epidemiological evidence that frequent cannabis use in general and during puberty in particular increases the risk to suffer psychosis and psychotic symptoms. Based on these observations, there is growing interest in the role of the endogenous cannabinoid system (eCB system) - the point of action for psychoactive cannabinoids - in psychiatric disorders and schizophrenia in particular. It has been hypothesized nearly two decades ago that the eCB system may play a pathophysiological role in schizophrenia either in terms of an endogenous malfunction of the system itself and/or of a secondary malfunction as a result of the use of exogenous cannabinoids like Δ(9)-tetrahydrocannabinol, the major psychoactive phytocannabinoid in Cannabis sativa. To test this hypothesis, several studies have been performed investigating endogenous ligands to cannabinoid CB1-receptors such as anandamide both in cerebrospinal fluid and plasma of patients and controls. Here a mini-review of the role of anandamide in schizophrenia is provided.